Pluri Inc. is a Haifa-based cell-expansion company whose latest annual report turns the investment case into a capital-structure question rather than a pipeline debate. The overdue European Investment Bank loan now sits larger than the entire equity value, and management states that cash covers operating obligations for less than three months from the September issuance date. That combination leaves common holders as a residual claim on a platform story that still generates only a thin sliver of paid work. The equity debate is whether the bank loan is restructured or converted before the cash clock expires.
Revenue for the fiscal year ended in late June slipped as contract manufacturing work slowed, while the annual loss widened. Cash and short-term deposits finished the year at $8.9 million. The bank loan, principal plus accrued interest, is carried as a current liability of $27.4 million. Shareholders deficit deepened, and the accumulated deficit now sits near $467 million. The commercial print is too small to service either the burn or the loan, so the equity is being funded by related-party private placements and a late-August registered sale.
The next few months resolve three named events rather than a product cycle. First is whether the European lender agrees to a documented forbearance, sale, or conversion after the June maturity passed without repayment. Second is whether another equity check arrives before the stated sub-three-month runway is exhausted. Third is whether Nasdaq market-value compliance is restored before the early-January deadline. If the loan is enforced at face value, residual common equity is economically junior to a claim larger than the company.